Breast cancer
Progression after CDK4/6i + ET for HR+ HER2- MBC. What now?

Joanna (58 years old)

Joanna, 58 years old, was diagnosed with primary metastatic breast cancer.

Assessment summary:

  • Postmenopausal
  • No relevant comorbidities or family history
  • Diagnosis de novo HR+ HER2- metastatic breast cancer with multiple spine and liver metastases
    • Tumour biology (liver lesion): invasive carcinoma of NST, ER 90%, PgR 40%, HER2 IHC 1+, Ki67 30%
  • First-line treatment: CDK4/6i + letrozole
    • CT scan after 3 months: partial response
    • CT scan after 6 months (3 additional months): stable disease
    • CT scan after 12 months (6 additional months): stable disease in spine, new multiple lesions in liver (accompanied with severe organ dysfunction: GOT 10x ULN, GPT 9x ULN, bilirubin 2x ULN), absence of biliary tract obstruction. She presents with loss of appetite, weight loss, and increased fatigue.

Which option would you choose for this patient?